Misplaced Pages

This is an old revision of this page, as edited by Schneelocke (talk | contribs) at 23:38, 20 December 2004 (Initial stub. This contains a lot of "thought to" and "said to"; maybe someone with a medical background can provide info on results of studies etc.?). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.

Examples of NaSSAs include:

• Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)

NaSSAs are said to have fewer side-effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.

Also see

• Clinical depression

External links

• J. Fawcett, R. L. Barkin: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

This medical article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Medicine stubs
• Antidepressants